Unlock instant, AI-driven research and patent intelligence for your innovation.

AX213 and AX132 PCSK9 antagonists and variants

An antagonist, antagonistic technology, applied in the direction of antibodies, antibody mimics/scaffolds, anti-enzyme immunoglobulins, etc.

Inactive Publication Date: 2012-08-15
SCHERING AG
View PDF98 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Taken together, these data suggest that PCSK9 action leads to increased LDL-C by reducing LDLR protein levels

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • AX213 and AX132 PCSK9 antagonists and variants
  • AX213 and AX132 PCSK9 antagonists and variants
  • AX213 and AX132 PCSK9 antagonists and variants

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0200] ABMAXIS PDL1 phage library panning against PCSK9 protein

[0201] A synthetic human Fab library was panned against human PCSK9. The antigenic protein PCSK9 was coated on Maxisorp well strips (Nunc-Immuno Modules) overnight at 4°C at a concentration of 1-10 μg / ml. For each library, prepare multiple antigen wells. Coated wells were blocked with 5% milk in PBS for 1-2 hours at room temperature. After washing with PBS, 100 μl of phage library solution / well (usually 1-5×10 12 , in 2% milk-PBS) were added to 4 parallel wells and incubated for the indicated length of time (usually 1-2 hours). After several washes with PBST and PBS, freshly prepared 2 Bound phage were eluted from the wells with 1.4% triethylamine in O (incubated for 10 minutes at room temperature), followed immediately by neutralization by the addition of 50 [mu]l 1M Tris-HCl, pH 6.8.

[0202] The eluted, enriched phage collection was further amplified by the following steps: First, TG1 cells were infected...

Embodiment 2

[0205] Fab ELISA Screening of PCSK9 Binders

[0206] Over 10,000 clones from the 3rd round of panning were picked by a MegaPix picking robot (Genetix) and inoculated into 384-well plates containing 60 μl 2YT / 2% glucose / carbenicillin and incubated at 30°C with shaking at 450 rpm overnight. Duplicate plates were prepared by transferring approximately 1-3 μl of the overnight culture from each well to a new plate containing 50 μl / well of 2YT / 0.1% glucose / carbenicillin. Replica plates were incubated for 6 hours at 30°C on a shaker, then 10 μl / well of IPTG was added to a final concentration of 1 mM. After overnight incubation at 22°C, soluble Fab was released in the IPTG-induced plates by adding lysozyme to each well.

[0207] To test the antigen-binding activity of soluble Fabs generated from the above experiments, antigen plates were prepared by coating overnight with 5 μg / ml human PCSK9 antigen. After blocking with 5% milk-PBS and washing with PBST, 15-20 μl of Fab samples wer...

Embodiment 3

[0218] Fab protein expression and purification from TG1 cells

[0219] A 50 ml overnight culture from a single clone was grown in 2YT / 2% glucose / carbenicillin 100 μg / ml in a 37°C shaker incubator. On the following day, each clone was inoculated with 750 mL to 1 L of 2YT / 0.1% glucose / 100 μg / mL carbenicillin by transferring 5-10 ml of the overnight culture. The culture was grown for approximately 3-4 hours at 30°C with shaking until the OD600 was about 1. IPTG was added to the cultures to a final concentration of 0.1-0.5 mM. Following overnight IPTG induction at 22°C, cell pellets were collected by centrifugation at 10,000 rpm for 10-15 minutes to proceed with periplasmic preparation.

[0220] Soluble Fab was extracted from the periplasm. Periplasmic preparation was performed as follows. The TG1 pellet was resuspended in 20 mL of pre-chilled PPB buffer (20% sucrose + 2 mM EDTA + 30 mM Tris, pH=8) and incubated on ice for 1 hour. The supernatant containing soluble Fab was co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

Antagonists of human proprotein convertase subtilisin-kexin type 9 ("PCSK9") are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Description

[0001] Cross-references to related applications [0002] not applicable [0003] Statement on Federally Funded R&D [0004] not applicable [0005] References to Microfiche Attachments [0006] not applicable Background technique [0007] Proprotein convertase subtilisin-kexin type 9 (hereinafter "PCSK9"), also known as neuronal apoptosis-regulated convertase 1 ("NARC-1"), is a proteolytic enzyme K-like subtilase , which was identified as the ninth member of the secreted linase family; see: Seidah et al., 2003 PNAS 100:928-933. The gene for PCSK9 is mapped to human chromosome 1p33-p34.3; Seidah et al., supra. PCSK9 is expressed in cells capable of proliferation and differentiation including, for example, hepatocytes, renal mesenchymal cells, ileal and colonic epithelium of the intestine, and telencephalic neurons of the embryonic brain; Seidah et al., supra. [0008] PCSK9 is initially synthesized as an approximately 72-kDa inactive enzyme precursor, or zymogen, which...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395C07K16/00
CPCC07K16/40C07K2317/21C07K2317/52C07K2317/55C07K2317/76C07K2317/94C07K2319/00C07K2299/00A61P3/04A61P3/06A61P43/00A61P9/10
Inventor P·P·罗Y·倪K·C·王M·谢X·王F·董A·戈罗索夫W·王Y·李P·钟L·B·彼得森R·卡邦S·沙马J·孔德拉J·卢G·帕萨萨拉蒂S·索瓦森N·伯恩
Owner SCHERING AG